Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2025 08:33 ET | Source: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
March 11, 2025 06:00 ET | Source: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.